New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
07:54 EDTMYGNMyriad Genetics guidance still looks conservative, says Cowen
Cowen believes Myriad Genetics increased guidance remains conservative citing improved margins and tax rates, and assumptions that include no increase to the Companion Diagnostics revenue range and expectations that BART percentage usage remains the same. Shares are Outperform rated.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:51 EDTMYGNTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:08 EDTMYGNCrescendo data shows Vectra DA is better predictor of joint damage in RA
Subscribe for More Information
November 14, 2014
07:14 EDTMYGNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 10, 2014
10:04 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTMYGNMyriad Genetics initiated with an Underweight at Morgan Stanley
Subscribe for More Information
November 7, 2014
07:23 EDTMYGNMyriad myPath Melanoma study shows 43% reduction in indeterminate diagnoses
Myriad Genetics presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology, or ASDP, annual meeting in Chicago, IL. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes. Key findings of this clinical utility study included a 43% reduction in indeterminate diagnoses and a 49% change in physicians' treatment recommendations for patients. The study evaluated the impact of the Myriad myPath Melanoma diagnostic test on dermatopathologists' diagnoses and intended treatment recommendations for 218 patients with pigmented skin lesions that were considered difficult to diagnose. The dermatopathologists recorded their diagnoses and treatment plans before and after receiving the myPath Melanoma test results.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use